Paper Details

  1. Home
  2. Paper Details

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol.

Author: GallowayDenise A, GriecoVerena, HaugeKirsten, MadeleineMargaret M, MagaretAmalia, MaoConstance, SchoutenJeffrey, Stankiewicz KaritaHelen C, WaldAnna, XiLong Fu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Human papillomavirus (HPV), particularly type 16, is a common cause of precancerous lesions in the anus and vulva. Over 30% of people treated for these lesions experience recurrence, with even higher rates among people with HIV and men who have sex with men. These recurrences can cause significant health problems and costs. Research suggests that the HPV vaccine may be beneficial in reducing the recurrence of these lesions in people who have been previously infected.
Paper Details　
Original Abstract of the Article :
Human papillomavirus (HPV), particularly HPV type 16, causes most anal and vulvar high-grade squamous intraepithelial lesions (HSIL), which are precursors to cancer. After initial treatment of HSIL, more than 30% of patients will have disease recurrence, with even higher recurrence among HIV-positiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481452/

データ提供：米国国立医学図書館（NLM）

HPV Vaccine: A Potential Weapon Against Recurrence

Human papillomavirus (HPV) is a common virus that can cause various cancers, including cervical, anal, and vulvar cancers. This study focuses on the potential therapeutic benefits of HPV vaccines in preventing the recurrence of vulvar and anal neoplasia (VIVA) after initial treatment. The researchers propose a trial protocol to investigate the efficacy of HPV vaccines in reducing the risk of disease recurrence in individuals who have previously been infected with HPV. This research holds promise for improving outcomes for patients with HPV-related cancers and reducing the burden of these diseases.

HPV Vaccines: A New Frontier for Cancer Prevention

The study proposes a trial protocol to investigate the use of HPV vaccines in preventing the recurrence of VIVA, a significant challenge for patients who have already undergone treatment. The researchers believe that HPV vaccines, which have been proven effective in preventing HPV infection, could also play a role in reducing the risk of recurrent disease in individuals who have already been infected. This research holds the potential to revolutionize the management of HPV-related cancers and improve patient outcomes.

Hope on the Horizon: New Strategies for Cancer Prevention

This study represents a promising avenue for exploring new strategies for cancer prevention and treatment. By investigating the potential therapeutic benefits of HPV vaccines in preventing disease recurrence, the researchers are paving the way for more effective management of HPV-related cancers. This research could lead to a reduction in the incidence of these diseases and improved quality of life for patients.

Dr. Camel's Conclusion

This study offers hope for individuals who have already battled HPV-related cancers. It's like discovering a hidden oasis in the desert of cancer, providing a potential source of relief and protection from the threat of recurrence. By exploring the therapeutic potential of HPV vaccines, we can offer new tools for preventing disease and improving outcomes for patients. It's like equipping ourselves with a sturdy camel caravan, ready to navigate the challenges of cancer and offer a safe haven for those in need.

Date :
  1. Date Completed 2020-02-20
  2. Date Revised 2021-03-06
Further Info :

Pubmed ID

30977845

DOI: Digital Object Identifier

PMC6481452

Related Literature

Article Analysis
・Effective treatment of hpv
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.